ArticleFrontiers in oncology2026
Intensified MR-guided pulsed adaptive cancer treatment- a potential new treatment option for large(>5cm) central non-small cell lung cancer, a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There are currently no effective treatment options for large, inoperable, centrally located thoracic lesions with poor or suboptimal response to immunotherapy. The use of SBRT for tumors larger than 5 cm in this location is limited by toxicity. Therefore, new and innovative treatment strategies are a major unmet medical need. Adaptive radiotherapy (ART) guided by MR-Linac systems, enables real-time adjustment of the treatment plan according to daily anatomical changes and tumor response. This approach is particularly beneficial in thoracic oncology, where tumor shrinkage and respiratory motion can significantly affect dose delivery. Moreover, ART may enhance the therapeutic synergy between radiotherapy and immunotherapy. Case presentation: We report the case of a 65-year-old woman diagnosed with stage IV non-small cell lung cancer (NSCLC) of mixed squamous and adenocarcinoma histology. The patient initially presented with seizures, and an MRI revealed 10 intracranial metastases alongside a 55 mm tumor in the left lung. Following stereotactic brain radiotherapy and the initiation of nivolumab plus ipilimumab, the treatment was continued with nivolumab monotherapy due to grade 3 pulmonary toxicity. Imaging demonstrated a tumor progression limited to the lung. She was then qualified for MR-guided adaptive stereotactic radiotherapy (3 × 10 Gy), delivered at 10-day intervals. Significant tumor regression required redefinition of the GTV before fractions 2 and 3. No acute or late toxicity was observed. A 6-month follow-up PET-CT revealed marked regression in tumor size (from 79 mm to 17 mm) and metabolic activity (SUVmax reduced from 33.1 to 5.13). Comparative imaging showed less extensive post-radiation lung changes than typically observed after conventional radiotherapy. Conclusion: This case illustrates the potential of MR-guided adaptive radiotherapy to enhance treatment precision, reduce toxicity, and enable immune-radiotherapy synergy. Integration of the PULSAR concept-with spaced fractions and immunotherapy-may improve tumor response. Further clinical trials are required to confirm these benefits on larger patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.